#United States #New York #Class Action #Pomerantz LLP #Biohaven Ltd.

Pomerantz Law Firm Files Class Action Lawsuit Against Biohaven Ltd.

On July 31, 2025, Pomerantz LLP, a prominent law firm specializing in corporate securities class actions, announced the initiation of a class action lawsuit against Biohaven Ltd. (NYSE: BHVN) and certain of its executives. This lawsuit, filed in the United States District Court for the District of Connecticut and recorded under the docket number 25-cv-01120, is on behalf of all individuals and entities, excluding the defendants, who purchased or acquired Biohaven securities between March 24, 2023, and May 14, 2025—dates that frame what is referred to as the “Class Period”.

The class action aims to recover damages resulting from alleged violations of federal securities laws by the defendants and seeks remedies under crucial sections of the Securities Exchange Act of 1934, including Sections 10(b) and 20(a), and Rule 10b-5, developed to enforce protections for investors.

Investors who acquired Biohaven securities during the designated Class Period are encouraged to act quickly, as they have until September 12, 2025, to formally request appointment as Lead Plaintiff in the lawsuit. For further inquiries, individuals can refer to Pomerantz’s website or contact attorney Danielle Peyton directly at 646-581-9980.

Details of the Lawsuit

Biohaven is recognized as a biopharmaceutical entity that focuses on the research, development, and commercialization of innovative therapies in immunology, neuroscience, and oncology. Within its portfolio, Biohaven has noteworthy investigational drugs such as troriluzole for treating spinocerebellar ataxia and BHV-7000 for bipolar disorder.

Despite these promising avenues, a critical development arose in May 2022 when the Phase 3 trial pertaining to troriluzole failed to reach its primary endpoint, raising substantive questions about the drug's viability. However, it's alleged that throughout this period, the defendants continued to promote the drug's supposed promise and favorable regulatory outlook based on supplementary analyses and newly available data.

In May 2023, Biohaven disclosed that it had submitted a New Drug Application (NDA) for troriluzole to the U.S. Food and Drug Administration (FDA), which sparked renewed investor interest in the company. Meanwhile, in October 2023, the European Medicines Agency (EMA) accepted Biohaven's Marketing Authorization Application (MAA) for the same drug.

However, a series of misrepresentations and omissions are believed to have undermined the company's credibility. Allegations include overstating both the regulatory outlook for troriluzole and the potential efficacy of BHV-7000 as a treatment for bipolar disorder. When these truths emerged, it was anticipated that they would adversely affect Biohaven’s business and financial standing, leading to significant investor losses.

On July 27, 2023, following the refusal of the FDA to review the NDA based on the Phase 3 trial results, Biohaven’s share price plummeted by 22.61%, losing $5.38 and closing at $18.42. Subsequently, several negative announcements, including a resubmission of the NDA that fell short of expectations and the withdrawal of the MAA, continued to dent investor confidence.

A final blow occurred on May 14, 2025, when Biohaven reported that the FDA would extend the prescription drug user fee act date for the NDA, further delaying any potential approval. This led to another stock drop, with shares falling nearly 20% in a single day.

Conclusion

The ongoing case against Biohaven highlights the critical role of transparency and integrity in corporate communications and actions. As a leading firm in securities litigation, Pomerantz LLP continues to advocate for investors and uphold accountability in the corporate sector. For potential plaintiffs considering involvement in this class action, further information is available through Pomerantz’s website, which details the process and requirements for joining the suit.

Pomerantz has a storied history, founded by Abraham L. Pomerantz, who was regarded as a pioneer in the field of class action, championing the rights of investors against securities fraud and corporate malfeasance. The legal landscape surrounding such actions continues to evolve, ensuring that investors maintain a recourse against misleading corporate practices.